I need more info on LL-BMT1.
LL-BMT1 is a weekly medicated, preservative-free, extended-wear contact lens that releases bimatroprost to treat open-angle glaucoma and hypertension. The bimatroprost is printed directly on the lens—an ocufilcon D soft hydrophilic contact lens—via an inkjet printer.
Tell me about the phase 2b study.
The Sustained Innovative Glaucoma and Ocular Hypertension Treatment (SIGHT)-2 dose-finding phase 2b study is the second in the SIGHT clinical program designed to treat mild to moderate glaucoma with LL-BMT1.
The study follows the completion of the SIGHT-1 study in March 2021. (via)
What happened with the first SIGHT trial?
LL-BMT1 was given to five patients with an average age of 77.4 who had not previously worn contact lenses. Each wore the lenses for seven days.
Results confirmed LL-BMT1’s safety profile, demonstrating 100% tolerability and no significant adverse events from a single dose.
As an added bonus, findings also included an efficacy signal from a single dose—which was not one of the study’s planned endpoints. (via)
What about patients’ IOP?
IOP elevation was noted as a secondary outcome, with at least one eye in each patient required to be untreated and with an IOP of 22 mmHg to 34 mmHg at baseline visit. Investigators assessed IOP levels in patients’ eyes on Day 1 and Day 4, which included removing and reinserting the lenses.
When does patient enrollment start for the phase 2b study?
Imminently!
What does this mean for patients?
LL-BMTI and other drug-eluting contact lenses have the potential to become an alternative therapeutic option for treating ocular diseases like dry eye disease, glaucoma, and seasonal ocular allergies.
Any other notable updates on this?
MediPrint plans to finalize the single dosage of LL-BMTI by the first half of 2023. A potential phase 3 study is also being explored.